Ecclesiastl.8fe News - ELLA

- (25-NSE)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION...

Celgene and Abraxis Announce Shareholder Vote in Favor of Merger

Celgene Corporation (NASDAQ: CELG) and Abraxis Bioscience, Inc. (NASDAQ: ABII) today announced that Abraxis’ shareholders...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Celgene Corporation Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed...

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR...

- Proxy Statement - Merger or Acquistion (definitive) (DEFM14A)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

- Proxy Soliciting Materials (revised) (PRER14A)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

- Quarterly Report (10-Q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Celgene Corporation Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Celgene Corporation Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed...

2nd UPDATE: Celgene 2Q Profit Up 8.8%; Again Boosts 2010 View

Celgene Corp.'s (CELG) second-quarter earnings rose 8.8%, as sales growth continued for its flagship blood cancer drug Revlimid. The Summit, N.J...

UPDATE: Celgene 2Q Profit Up 8.8%; Again Increases 2010 View

Celgene Corp.'s (CELG) second-quarter earnings rose 8.8%, as sales growth continued for its flagship blood cancer drug Revlimid. The Summit, N.J...

- Proxy Statement - Merger or Acquistion (preliminary) (PREM14A)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ecclesiastl.8fe (ELLA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ELLA News

- (25-NSE)

Celgene and Abraxis Announce Shareholder Vote in Favor of Merger

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Proxy Statement - Merger or Acquistion (definitive) (DEFM14A)

- Proxy Soliciting Materials (revised) (PRER14A)

- Quarterly Report (10-Q)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

2nd UPDATE: Celgene 2Q Profit Up 8.8%; Again Boosts 2010 View

UPDATE: Celgene 2Q Profit Up 8.8%; Again Increases 2010 View

- Proxy Statement - Merger or Acquistion (preliminary) (PREM14A)

Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand

ELLA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ecclesiastl.8fe (ELLA) News

Ecclesiastl.8fe (ELLA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ELLA News

- (25-NSE)

Celgene and Abraxis Announce Shareholder Vote in Favor of Merger

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Proxy Statement - Merger or Acquistion (definitive) (DEFM14A)

- Proxy Soliciting Materials (revised) (PRER14A)

- Quarterly Report (10-Q)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

2nd UPDATE: Celgene 2Q Profit Up 8.8%; Again Boosts 2010 View

UPDATE: Celgene 2Q Profit Up 8.8%; Again Increases 2010 View

- Proxy Statement - Merger or Acquistion (preliminary) (PREM14A)

Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand

ELLA Discussion

Your Recent History